Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Taiho’s TS-1 Launched in UK, Approved in Hong Kong
April 12, 2012
- Toyota Tsusho Signs Agreement with Korean Venture to Become Sole Agent in Japan
April 12, 2012
- Sanofi Pasteur Targets Double Sales in Japan, Enters 4 Products Including IPV
April 11, 2012
- Takeda Pharmaceutical to Be Refunded 57.1 Bil. Yen for Transfer Pricing Taxation
April 11, 2012
- Sales Level Off for Year Ended Feb 2012 on Effects of Earthquake: Hisamitsu
April 11, 2012
- Sales of Ethical Drugs Up 8.7% in February: Crecon Report
April 10, 2012
- GSK Ties Up with Chiome for Antibody Generation Technology
April 10, 2012
- Fuso, Kaken to Jointly Market Topical Hemostatic Agent
April 10, 2012
- Ethical Drug Production in 2019 Predicted at 11 Trillion Yen: Yano Research Survey
April 10, 2012
- Anticoagulant Market to Heat Up with Lifting of Ban on Long-term Prescription of Prazaxa, Debut of New Products
April 10, 2012
- Generics Made in India to Storm Japanese Market with Overwhelming Price Advantage
April 10, 2012
- Bayer Yakuhin to Focus on 2 Prospective Blockbusters, Target 200 Billion Yen in Sales in 2013: President Guth
April 9, 2012
- US FDA Recommends Approval of Mirabegron from Astellas
April 9, 2012
- Sanofi-aventis, Alfresa Agree on Joint Development of Antiepileptic Drug
April 9, 2012
- Ohara Pharmaceutical Begins Development of Glucarpidase, Aims to File for Approval in 2014
April 9, 2012
- Eisai Establishes Aricept Director Position
April 6, 2012
- MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…